Search Results

Lifecore Biomedical, Inc. announced it has reached a cooperation agreement with 22NW, LP, which provides for the addition of Humberto Antunes, Jason Aryeh, Paul Johnson and Matthew Korenberg to the Board of Directors of the Company effective immediately following the 2023 Annual Meeting of Stockholders.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, announced changes to its Board of Directors as part of the Company’s aspiration to become a fully integrated biotechnology company.

Morphic Therapeutic today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief Medical Officer.

BioAI, an emerging biotech company applying multimodal artificial intelligence (AI) to novel biomarker discovery, development, and diagnostics, announced a strategic collaboration with Genomic Testing Cooperative (GTC), a leading provider of molecular diagnostics for solid tumors and hematologic malignancies.

Allecra Therapeutics and Acino announced the signing of an exclusive licensing agreement under which Acino gains the rights to commercialise Allecra’s antibiotic drug EXBLIFEP® within the Republic of South Africa and the member states of the GCC alliance, which includes Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates, effective from 12 June 2024.

Nevro Corp. announced that it has entered into a Cooperation Agreement with Engaged Capital, LLC, pursuant to which Kirt P. Karros has been appointed to Nevro’s Board of Directors as well as the Audit Committee of the Board effective February 20, 2024.